Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of docetaxel with or without nintedanib in second-line HER2-negative metastatic or locally recurrent breast cancer
2012-002214-38Phase 2Terminated
- Sponsor
- Centre Oscar Lambret
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of nintedanib in breast cancer (2 arms), sponsored by Centre Oscar Lambret. Primary endpoint: Median progression-free survival (PFS). Started Jun 2020; status: terminated.
02
Drugs
nintedanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-002214-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002214-38.